Drug Profile
Temelimab - GeNeuro
Alternative Names: GENHP-01; GNbAC-1; GNN-001Latest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator GeNeuro
- Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Multiple sclerosis; Post acute COVID 19 syndrome
- Phase I Chronic inflammatory demyelinating polyradiculoneuropathy
- Suspended Type 1 diabetes mellitus
Most Recent Events
- 16 Jan 2024 GeNeuro plans a phase III trial for Multiple sclerosis (IV) (GeNeuro pipeline, January 2024)
- 01 Dec 2023 GeNeuro completes enrolment in its phase II trial for Post-acute-COVID-19-syndrome in Italy, Spain and Switzerland (NCT05497089)
- 01 Mar 2023 Phase-II clinical trials in Post-acute-COVID-19-syndrome in Italy (IV, Infusion) (NCT05497089)